annual CFF:
$399.24M+$11.10M(+2.86%)Summary
- As of today (September 16, 2025), RARE annual cash flow from financing activities is $399.24 million, with the most recent change of +$11.10 million (+2.86%) on December 31, 2024.
- During the last 3 years, RARE annual CFF has risen by +$280.69 million (+236.76%).
- RARE annual CFF is now -41.23% below its all-time high of $679.31 million, reached on December 31, 2019.
Performance
RARE Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$83.65M+$83.49M(+53179.62%)Summary
- As of today (September 16, 2025), RARE quarterly cash flow from financing activities is $83.65 million, with the most recent change of +$83.49 million (+53179.62%) on June 30, 2025.
- Over the past year, RARE quarterly CFF has dropped by -$301.29 million (-78.27%).
- RARE quarterly CFF is now -82.99% below its all-time high of $491.88 million, reached on September 30, 2022.
Performance
RARE quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$91.17M-$301.29M(-76.77%)Summary
- As of today (September 16, 2025), RARE TTM cash flow from financing activities is $91.17 million, with the most recent change of -$301.29 million (-76.77%) on June 30, 2025.
- Over the past year, RARE TTM CFF has dropped by -$649.56 million (-87.69%).
- RARE TTM CFF is now -87.69% below its all-time high of $740.73 million, reached on June 30, 2024.
Performance
RARE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
RARE Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.9% | -78.3% | -87.7% |
| 3 y3 years | +236.8% | +1333.1% | -9.5% |
| 5 y5 years | -41.2% | +133.6% | -77.6% |
RARE Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -20.3% | +236.8% | -83.0% | >+9999.0% | -87.7% | +53.4% |
| 5 y | 5-year | -41.2% | +236.8% | -83.0% | >+9999.0% | -87.7% | +53.4% |
| alltime | all time | -41.2% | >+9999.0% | -83.0% | >+9999.0% | -87.7% | >+9999.0% |
RARE Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $83.65M(>+9900.0%) | $91.17M(-76.8%) |
| Mar 2025 | - | $157.00K(-95.1%) | $392.46M(+0.1%) |
| Dec 2024 | $399.24M(+2.9%) | $3.19M(-23.7%) | $392.24M(-45.5%) |
| Sep 2024 | - | $4.17M(-98.9%) | $719.66M(-2.8%) |
| Jun 2024 | - | $384.94M(<-9900.0%) | $740.73M(+90.5%) |
| Mar 2024 | - | -$58.00K(-100.0%) | $388.81M(+0.2%) |
| Dec 2023 | $388.14M(-22.6%) | $330.61M(+1210.2%) | $388.14M(+553.3%) |
| Sep 2023 | - | $25.23M(-23.6%) | $59.41M(-88.7%) |
| Jun 2023 | - | $33.02M(-4673.4%) | $526.06M(+5.4%) |
| Mar 2023 | - | -$722.00K(-138.4%) | $498.87M(-0.5%) |
| Dec 2022 | $501.21M(+322.8%) | $1.88M(-99.6%) | $501.21M(-14.3%) |
| Sep 2022 | - | $491.88M(+8326.9%) | $585.05M(+480.8%) |
| Jun 2022 | - | $5.84M(+262.1%) | $100.72M(-6.3%) |
| Mar 2022 | - | $1.61M(-98.1%) | $107.52M(-9.3%) |
| Dec 2021 | $118.55M(-80.3%) | $85.72M(+1035.4%) | $118.55M(-77.3%) |
| Sep 2021 | - | $7.55M(-40.2%) | $522.54M(-2.2%) |
| Jun 2021 | - | $12.63M(-0.2%) | $534.12M(-4.2%) |
| Mar 2021 | - | $12.65M(-97.4%) | $557.31M(-7.2%) |
| Dec 2020 | $600.27M(-11.6%) | $489.71M(+2459.2%) | $600.27M(+40.9%) |
| Sep 2020 | - | $19.14M(-46.6%) | $426.00M(+4.5%) |
| Jun 2020 | - | $35.81M(-35.6%) | $407.77M(+6.9%) |
| Mar 2020 | - | $55.62M(-82.4%) | $381.30M(-43.9%) |
| Dec 2019 | $679.31M(+101.7%) | $315.44M(>+9900.0%) | $679.31M(+80.6%) |
| Sep 2019 | - | $904.00K(-90.3%) | $376.11M(-6.0%) |
| Jun 2019 | - | $9.34M(-97.4%) | $400.23M(-0.9%) |
| Mar 2019 | - | $353.62M(+2788.6%) | $404.05M(+19.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | $336.85M(+147.2%) | $12.24M(-51.1%) | $336.85M(-13.4%) |
| Sep 2018 | - | $25.02M(+90.0%) | $389.05M(+6.5%) |
| Jun 2018 | - | $13.17M(-95.4%) | $365.36M(+3.3%) |
| Mar 2018 | - | $286.42M(+344.5%) | $353.72M(+159.6%) |
| Dec 2017 | $136.27M(-1.7%) | $64.44M(+4734.1%) | $136.27M(-7.2%) |
| Sep 2017 | - | $1.33M(-12.6%) | $146.77M(-29.7%) |
| Jun 2017 | - | $1.53M(-97.8%) | $208.88M(+0.7%) |
| Mar 2017 | - | $68.97M(-8.0%) | $207.33M(+49.5%) |
| Dec 2016 | $138.68M(-70.3%) | $74.94M(+18.1%) | $138.68M(+114.6%) |
| Sep 2016 | - | $63.45M(<-9900.0%) | $64.62M(-77.7%) |
| Jun 2016 | - | -$25.00K(-108.0%) | $289.83M(-0.9%) |
| Mar 2016 | - | $314.00K(-64.6%) | $292.45M(-37.5%) |
| Dec 2015 | $467.57M(+152.8%) | $887.00K(-99.7%) | $467.57M(-0.4%) |
| Sep 2015 | - | $288.65M(>+9900.0%) | $469.38M(+94.6%) |
| Jun 2015 | - | $2.60M(-98.5%) | $241.24M(+1.1%) |
| Mar 2015 | - | $175.44M(+6405.0%) | $238.66M(+29.0%) |
| Dec 2014 | $184.97M(>+9900.0%) | $2.70M(-95.5%) | $184.97M(+1.5%) |
| Sep 2014 | - | $60.51M(>+9900.0%) | $182.31M(+49.6%) |
| Jun 2014 | - | $10.00K(-100.0%) | $121.88M(-0.0%) |
| Mar 2014 | - | $121.75M(>+9900.0%) | $121.92M(>+9900.0%) |
| Dec 2013 | $171.00K(-99.8%) | $38.00K(-50.0%) | $171.00K(-99.8%) |
| Sep 2013 | - | $76.00K(+35.7%) | $74.14M(-17.0%) |
| Jun 2013 | - | $56.00K(+5500.0%) | $89.30M(+0.1%) |
| Mar 2013 | - | $1000.00(-100.0%) | $89.24M(+0.0%) |
| Dec 2012 | $89.24M(+415.0%) | $74.01M(+386.0%) | $89.24M(+486.0%) |
| Sep 2012 | - | $15.23M | $15.23M |
| Dec 2011 | $17.33M | - | - |
FAQ
- What is Ultragenyx Pharmaceutical Inc. annual cash flow from financing activities?
- What is the all time high annual CFF for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. annual CFF year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. quarterly CFF year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. TTM cash flow from financing activities?
- What is the all time high TTM CFF for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. TTM CFF year-on-year change?
What is Ultragenyx Pharmaceutical Inc. annual cash flow from financing activities?
The current annual CFF of RARE is $399.24M
What is the all time high annual CFF for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high annual cash flow from financing activities is $679.31M
What is Ultragenyx Pharmaceutical Inc. annual CFF year-on-year change?
Over the past year, RARE annual cash flow from financing activities has changed by +$11.10M (+2.86%)
What is Ultragenyx Pharmaceutical Inc. quarterly cash flow from financing activities?
The current quarterly CFF of RARE is $83.65M
What is the all time high quarterly CFF for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high quarterly cash flow from financing activities is $491.88M
What is Ultragenyx Pharmaceutical Inc. quarterly CFF year-on-year change?
Over the past year, RARE quarterly cash flow from financing activities has changed by -$301.29M (-78.27%)
What is Ultragenyx Pharmaceutical Inc. TTM cash flow from financing activities?
The current TTM CFF of RARE is $91.17M
What is the all time high TTM CFF for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high TTM cash flow from financing activities is $740.73M
What is Ultragenyx Pharmaceutical Inc. TTM CFF year-on-year change?
Over the past year, RARE TTM cash flow from financing activities has changed by -$649.56M (-87.69%)